A Polymorphism in Plasma Platelet-activating Factor Acetylhydrolase is Involved in Resistance to Immunoglobulin Treatment in Kawasaki Disease
- 31 July 2005
- journal article
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 147 (1), 78-83
- https://doi.org/10.1016/j.jpeds.2005.03.037
Abstract
No abstract availableFunding Information
- Ministry of Education, Culture, Sports, Science and Technology (2002-2004)
This publication has 34 references indexed in Scilit:
- A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki diseaseThe Journal of Pediatrics, 2003
- Platelet-activating factor acetylhydrolase gene mutation in Japanese nephrotic childrenKidney International, 1998
- Platelet-activating factor receptor: gene expression and signal transductionBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- A signal terminatorNature, 1995
- Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsisCritical Care Medicine, 1994
- Gamma globulin re-treatment in Kawasaki diseaseThe Journal of Pediatrics, 1993
- Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki diseaseThe Journal of Pediatrics, 1992
- Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin 6 in serumEuropean Journal of Pediatrics, 1992
- Nationwide survey of Kawasaki disease and acute rheumatic feverThe Journal of Pediatrics, 1991
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASEThe Lancet, 1984